Elevation Oncology, Inc. (ELEV)
0.3650
-0.0079 (-2.12%)
Inactive · Last trade price on Jul 22, 2025
Elevation Oncology Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Elevation Oncology stock had an average target of 1.77, with a low estimate of 0.36 and a high estimate of 5.
Price Target: $1.77 (+384.93%)
Analyst Consensus: Hold
* Price targets were last updated on Jun 10, 2025.
Analyst Ratings
The average analyst rating for Elevation Oncology stock from 6 stock analysts was "Hold". This means that analysts believed this stock was likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Buy | 5 | 2 | 2 | 2 | 0 | 0 |
| Hold | 0 | 4 | 4 | 4 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Hold Reiterates n/a | Hold | Reiterates | n/a | n/a | Jun 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $1 → $0.36 | Strong Buy → Hold | Downgrades | $1 → $0.36 | -1.37% | Jun 10, 2025 |
| William Blair | William Blair | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jun 9, 2025 |
| Stephens & Co. | Stephens & Co. | Buy → Hold Downgrades $5 | Buy → Hold | Downgrades | $5 | +1,269.86% | Mar 24, 2025 |
| JMP Securities | JMP Securities | Buy → Hold Reiterates n/a | Buy → Hold | Reiterates | n/a | n/a | Mar 21, 2025 |
Financial Forecast
Revenue This Year
n/a
from 33.68M
Revenue Next Year
n/a
EPS This Year
-0.75
from -0.78
EPS Next Year
-0.55
from -0.75
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | n/a | ||
| Avg | n/a | n/a | n/a | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | -0.65 | -0.32 | -0.27 | |
| Avg | -0.75 | -0.55 | -0.47 | |
| Low | -0.98 | -0.99 | -0.60 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.